-
What's new in RA? What is updated in the EULAR guidelines? One article mastered
Time of Update: 2023-01-06
Come to the "doctor's station" and take a look 👇Safety of bDMARDs versus tsDMARDsAlarge study (Figure 2) including data from the registries of RA patients in 16 countries found no significant difference in discontinuation rates due to adverse effects between csDMARDs, TNF-α inhibitors, and JAK inhibitors.
-
What's new in RA? What is updated in the EULAR guidelines? One article mastered
Time of Update: 2023-01-06
Come to the "doctor's station" and take a look 👇Safety of bDMARDs versus tsDMARDsAlarge study (Figure 2) including data from the registries of RA patients in 16 countries found no significant difference in discontinuation rates due to adverse effects between csDMARDs, TNF-α inhibitors, and JAK inhibitors.
-
Wary! These 6 behaviors increase the risk of stroke in the short term, including drinking Coke
Time of Update: 2022-10-25
[1]Six of the nine triggers were investigated to significantly increase the risk of strokeThe researchers investigated whether nine triggers were associated with stroke in young adults: alcohol consumption, smoking, caffeinated coffee, coffee-containing cola, strenuous exercise, sexual activity, use of illicit drugs (cocaine, heroin, ecstasy, etc.
-
How can patients with cerebral hemorrhage address blood pressure variability? Nicardipin may be preferred
Time of Update: 2022-09-21
Figure 1 Comparison of mean BPV between different treatment regimensFrom this study, it can be seen that compared with labetalol or hydralazine, nicardipine can lower blood pressure more stably after spontaneous intracerebral hemorrhage, avoiding the adverse effects of excessive BPV on the prognosis of patients.
-
A certain protein causes deadly cancer
Time of Update: 2022-09-08
Researchers at the University of California, Irvine have discovered how a certain protein is activated in tumor cells, which could lead to more effective treatments for some of the deadliest cancers .
-
A number of domestic pharmaceutical companies accelerate the deployment of rare disease drugs to win market opportunities
Time of Update: 2022-09-06
The industry said that with the help of favorable policies, drugs for rare diseases will be launched at an accelerated pace, and domestic companies have also begun to pay attention to the field of rare diseases, deploying research and development to win market opportunities .
-
Breaking the limits of deep-sea capture, transforming innovations in nutraceutical ingredients from the ocean
Time of Update: 2022-08-31
(Source: Gut Industry) "China Food News" (May 10, 2021 06 edition)(Editor-in-charge: Yang Xiaojing) Studies have shown that many marine-derived ingredients are closely related to human health, such as the well-known fish oil .
-
Liu Qiang's group reveals the mechanism of PI3K/mTOR inhibitor reversing CDK4/6 inhibitor resistance in breast cancer
Time of Update: 2022-08-20
Recently, Liu Qiang's research group from Sun Yat-sen Memorial Hospital of Sun Yat-sen University published a research paper entitled "Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR Inhibitors" in Science China Life Sciences.
-
Local pharmaceutical companies are accelerating innovation and transformation, and competition is becoming increasingly fierce
Time of Update: 2022-05-08
From the perspective of pharmaceutical companies that have disclosed R&D investment data, local pharmaceutical companies are accelerating the pace of innovation and transformation .
The R&D investment of Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, CSPC and other companies has exceeded 3 billion yuan on average, reaching 6.
-
Brain: These factors are associated with early-stage multiple sclerosis progression and relapse
Time of Update: 2022-04-23
The aim of this study was to investigate the contribution of relapse-related worsening and progression independent of relapsing activity to the accumulation of confirmed disability in patients with clinically isolated syndrome and early-stage relapsing-remitting MS, assessed within one year of onset, with follow-up >/=5 Years (n = 5169) .
-
New achievements of Chinese scholars reveal nonlinear changes in the interaction between sustainable development goals
Time of Update: 2022-04-17
The SDGs cluster diagram of the synergy network can clearly reflect the change process of first decoupling and then recoupling between SDGs with the level of sustainable development (Figure) .
-
Researchers identify brain region linked to satiety
Time of Update: 2022-03-08
A new University of Arizona-led study published in the journal Molecular Metabolism has uncovered a brain region and neural circuit that regulates satiety, which could help scientists better target drugs for eating disorders or weight management .
-
After Xinda, who will take over
Time of Update: 2022-03-06
In the table below, we list some domestic innovative drugs and their affiliated companies that have entered the NDA or BLA stage in the United States and are in clinical trials: Table 1 Clinical progress of some Chinese innovative drugs in the United States Overseas markets can bring huge benefits to enterprises and inject new impetus into the long-term development of enterprises .
-
Cell Reports: Potential star anti-cancer targets may promote cancer
Time of Update: 2021-12-24
However, a recent study by a research team at the University of California, San Diego showed that Shp2 as a therapeutic target can also promote disease progression , which has raised concerns about the development of anticancer drugs that target Shp2 .
-
my country's first "Report on the Development of Rheumatoid Arthritis in China" was officially published
Time of Update: 2021-11-15
" Director of the National Clinical Research Center for Skin and Immune Diseases, Executive Director of the Chinese Medical Doctor Association and President of Rheumatology and Immunology Branch, Beijing Professor Zeng Xiaofeng, Director of the Department of Rheumatology and Immunology of Xiehe Hospital, pointed out that “The Annual Report of RA” is based on patient diagnosis and treatment data from tertiary hospitals to primary medical institutions.
